Letters, Testimony & Comments

November 16, 2004
To the Members of the U.N. General Assembly: The Biotechnology Industry Organization (BIO) represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and...
November 5, 2004
Intervention of BIO Agenda Item 7 Patent Disclosure Requirements relating to Genetic Resources Thank you Mr. Chairman. The Biotechnology Industry Organization (BIO) commends the effort of the Committee to engage in a constructive...
October 26, 2004
October 18, 2004
Dear Sir/Madam: The following comments are provided by the Biotechnology Industry Organization (BIO). BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50...
October 8, 2004
Relating to CMS' proposed rule revisions from the Federal Register CMS-1427-P, August 16, 2004
October 6, 2004
HEARING ON PROJECT BIOSHIELD II OCTOBER 6, 2004 This statement is submitted by the Biotechnology Industry Organization (BIO), an organization representing over 1,000 companies, universities, research institutions, state biotechnology...
October 4, 2004
Federal Register CMS-4068-P, August 3, 2004
September 27, 2004
Dear Sir/Madam: The following comments are provided by the Biotechnology Industry Organization (BIO). BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in...
September 24, 2004
Relating to CMS's proposed rule revisions
September 24, 2004
Under the Medicare physician fee schedule.
September 20, 2004
On September 20, 2004, BIO submitted an amicus curiae brief in a California Court of Appeal supporting Gilead Sciences Inc's efforts to overturn a lower-court ruling in a shareholders' derivative action. Under California law, a...
September 17, 2004
Comments to United States Pharmacopeia's draft Medicare Prescription Drug Benefit Model Guidelines
September 8, 2004
September 8th, 2004 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852 Re: Docket No. 2004N-0018, Federal Register: June 10, 2004 (Volume 69, Number 112, Pages 32467-32475...
September 7, 2004
Dear Mr. Simon: I write on behalf of the Biotechnology Industry Organization (BIO) in response to your request for views of European industry on proposed requirements to indicate the origin of material in patent applications. BIO is a trade...
September 2, 2004
The Biotechnology Industry Organization (BIO) appreciates this opportunity to testify about the hospital outpatient department prospective payment system (OPPS) proposed rule for 2005. BIO is the largest trade organization to serve and represent...